Literature DB >> 23354033

Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake.

Sona Balogova1, Virginie Huchet, Christoph Egrot, Laure Michaud, F Paycha, Khaldoun Kerrou, Francoise Montravers, Olivier Cussenot, Jean Noel Talbot.   

Abstract

The effect of erythropoietin stimulation on bone marrow uptake of FDG has been well documented. Similar metabolic activation of bone marrow with (18)F-fluorocholine (FCH) has not been previously reported. FCH PET/CT was performed in a patient with biochemical recurrent prostate cancer who was receiving erythropoietin for hemochromatosis. Diffuse skeletal uptake of FCH was seen. (18)F-Fluoride PET/CT performed the following day demonstrates multiple abnormal focal bone metastases. Generalized skeletal uptake of FCH results in poor contrast between the metastases compared to noninvolved bone. The metabolic activation of bone marrow by erythropoietin could result in false-negative FCH results for detecting bone metastases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354033     DOI: 10.1097/RLU.0b013e31827a2294

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Changes in Skeletal Tumor Activity on (18)F-choline PET/CT in Patients Receiving (223)Radium Radionuclide Therapy for Metastatic Prostate Cancer.

Authors:  Kyle S Miyazaki; Yu Kuang; Sandi A Kwee
Journal:  Nucl Med Mol Imaging       Date:  2015-01-09

2.  Semi-automated histogram analysis of normal bone marrow using 18F-FDG PET/CT: correlation with clinical indicators.

Authors:  Yoko Satoh; Satoshi Funayama; Hiroshi Onishi; Keita Kirito
Journal:  BMC Med Imaging       Date:  2022-02-23       Impact factor: 1.930

3.  When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer.

Authors:  Carmelo Caldarella; Giorgio Treglia; Alessandro Giordano; Luca Giovanella
Journal:  Cancer Manag Res       Date:  2013-06-25       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.